1
ALL1
AbbVie IncYear
1
ALL1
2024DEALS // DEV.
1
ALL1
DealsCountry
1
ALL1
U.S.A1
ALL1
Sionna TherapeuticsTherapeutic Area
1
ALL1
TechnologyStudy Phase
1
ALL1
ApprovedDeal Type
1
ALL1
Licensing AgreementProduct Type
1
ALL1
Small moleculeDosage Form
0
ALLLead Product
1
ALL1
GalicaftorTarget
0
ALLLead Product(s) : Galicaftor,Navocaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Sionna Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Sionna Expands CF Pipeline with AbbVie License Agreement
Details : Under the terms of the agreement, Sionna will assume all development for ABBV-2222 (galicaftor), which is being evaluated in combination with navocaftor for the treatment of Cystic Fibrosis.
Brand Name : ABBV-2222
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 16, 2024
Lead Product(s) : Galicaftor,Navocaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Sionna Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?